Aura Biosciences Posts Q2 Cash Surge

Aura Biosciences (NASDAQ:AURA), a biotechnology company focused on developing virus-like drug conjugates for cancer with an emphasis on ocular oncology, reported its second quarter 2025 financial results on August 13, 2025. The most notable development was the continued clinical progress of its lead candidate bel-sar, particularly in the pivotal Phase 3 CoMpass trial for early choroidal melanoma. The company posted a net loss per share of $0.47 (GAAP), slightly beating the consensus expectation of a $0.48 loss. As anticipated, no revenue was reported given Aura's pre-commercial status. The quarter was marked by increased research and development spending and a strengthened cash position after a $75 million equity raise. Overall, the period saw operational momentum in clinical programs, a significant boost to cash resources, but persistent high net losses typical for late-stage clinical biotech firms. Source: Analyst estimates for the quarter provided by FactSet. Aura Biosciences develops therapies for cancer based on its proprietary virus-like drug conjugate platform. Its lead product candidate, bel-sar, is in clinical trials targeting rare and aggressive cancers, notably in the eye and bladder. The company's main focus is on developing innovative treatments for ocular cancers where few effective and vision-sparing therapies exist.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool